{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Lexeo Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"LXEO"},"Address":{"label":"Address","value":"345 PARK AVENUE SOUTH,6TH FLOOR, NEW YORK, New York, 10010, United States"},"Phone":{"label":"Phone","value":"212-547-9879"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York."},"CompanyUrl":{"label":"Company Url","value":"https://www.lexeotx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Eric Adler","title":"Chief Medical Officer & Head-Research"},{"name":"Jose Manuel Otero","title":"Chief Technical Officer"},{"name":"Paul McCormac","title":"Chief Technical Officer"},{"name":"R. Nolan Townsend","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}